Safety and Immunogenicity of Two Doses of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Indian and Russian Children Aged 9 to 17 Months
- 10 Downloads
Evaluation of tolerability, safety and immunogenicity of a two-dose series of a quadrivalent meningococcal polysaccharide diptheria toxoid conjugate (ACYW-D) vaccine in Indian and Russian infants/toddlers.
Open-label, single-arm, phase III multi-national trial.
300 children aged 9–17 months, previously unvaccinated against meningococcal disease from four sites each in India (n=200) and the Russian Federation (n=100).
Two 0.5 mL doses of ACYW-D by intramuscular injection, 3–6 months apart.
Main outcome measures
Meningococcal antibody titers to serogroups A, C, W-135 and Y, determined using a serum bactericidal assay in the presence of human complement before vaccination and 28 days after the second vaccination. Titers ≥1:8 against either/all of the A, C, W-135 or Y were considered seroprotective.
After dose 2, 95.7–99.5% and 92.9–99.0% of infants/ toddlers achieved seroprotection across the four serogroups in India and the Russian Federation, respectively. No immediate adverse events were reported after any dose of ACYW-D. Solicited reactions were reported in 49.2% of participants, and were mainly of Grade 1 severity, and resolved within three days. Unsolicited adverse events were reported in 19.1% of infants: one event (Grade 3 diarrhea, resolving within one day) was considered related to study vaccine. No non-serious adverse events led to premature withdrawal from the study. Four serious adverse events were reported; none were considered related to study vaccine. No deaths occurred during the study.
A two-dose series of ACYW-D vaccine in Indian and Russian children (9-17 month) was well-tolerated with no safety concerns, and induced robust bactericidal antibody responses against the meningococcal serogroups contained in the vaccine.
KeywordsBactericidal assay Immunization Meningococcus Prevention
Unable to display preview. Download preview PDF.
- 3.Titova L, Samodova O, Buzinov R, Gordienko T. Epidemiology of meningococcal infection in arkhangelskoblast. Available from: http://wwwepinorthorg/eway/defaultaspx?pid=230&trg=Area_5268&MainArea_5 260=5263:0:15,2946:1:0:0:::0:0&Area_5263=5268:44984::1: 5264: 1:::0:0&Area_5268=5273:47185::1:5266:3:::0:0. Accessed June 19, 2017.Google Scholar
- 4.Koroleva IS, Maxina TA, Zakroeva M, Beloshitsky GV, Lytkina IN, Pyaeva AP. Epidemiology of invasive meningococcal disease in Moscow, 2005–2010. Available from: www.meningitis.org/assets/x/53942. Accessed June 19, 2017.Google Scholar
- 10.Koroleva I, Beloshitskij G, Zakroeva I, Melnikova A, Koroleva M, Shipulin G, et al. Invasive meningococcal disease in Russian Federation. In: European Meningococcal Disease Society. 20 years EMGM. Bad Loipersdorf, Austria. 17–19 September 2013. p71. Available from: http://emgm.eu/meetings/emgm2013/Abstract_Book_EMGM_2013.pdf. Accessed April 13, 2017.Google Scholar
- 13.Pelton SI, Gilmet GP. Expanding prevention of invasive meningococcal disease. Expert Rev Vaccines. 2009;8: 717–27.Google Scholar
- 15.Choudhuri D, Huda T, Theodoratou E, Nair H, Zgaga L, Falconer R, et al. An evaluation of emerging vaccines for childhood meningococcal disease. BMC Public Health. 2011;11:S29.Google Scholar
- 17.Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8:616–23.Google Scholar
- 19.Noya F, McCormack D, Reynolds DL, Neame D, Oster P. Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12–to 18–month–old children. Can J Infect Dis Med Microbiol. 2014;25:211–6.CrossRefGoogle Scholar